All news (page 6)

• 

  18 May 2026

  Merck: sac‑TMT meets OS and PFS endpoints in Phase 3 TroFuse‑005 for advanced/recurrent endometrial cancer

  TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
• 

  18 May 2026

  Repsol and Santos begin Pikka oil production in Alaska

  Partners reached first oil at a North Slope project; production to hit 80,000 bpd plateau in Q3 with first sales then. 28 wells drilled in phase 1; 45 wells planned; further phases expected.
• 

  18 May 2026

  OMV starts production at Austria’s largest gas discovery in 40 years

  Wittau well begins gas output; first phase 11 TWh for winter 2026/27, recoverable up to 48 TWh. EUR150m invested so far; project could double Austria’s gas production.
• 

  18 May 2026

  Asahi Kasei Therapeutics starts Phase III trial of Teribone (teriparatide) for high‑risk osteoporosis

  Domestic Phase III trial to assess extended therapy beyond 24 months for patients with severe osteoporosis at high fracture risk; evaluates efficacy and safety of continued treatment.
• 

  18 May 2026

  Teijin Frontier and Asahi Kasei Advance form TA Frontier

  Merged firm launches Oct 1, 2026; ownership split 80/20. It combines materials technologies and marketing across textiles, industrial, building and resins for sustainable growth.
• 

  18 May 2026

  Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors

  Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.

• 

  18 May 2026

  Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors

  TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
• 

  18 May 2026

  Seven MDBs Pledge Support for Middle East Conflict Impacts

  Offer financing, policy, private‑sector tools and technical assistance to manage shocks to energy, food and trade — providing relief, budget support, liquidity, trade finance, firm support and resilience investments
• 

  18 May 2026

  GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59

  Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
• 

  15 May 2026

  PTT Global Chemical Q1 2026 Results: Integrated Value Chain Secures Production and Balances Portfolio

  Q1 revenue THB 146,936m; net profit THB 3,232m. Operations sustained via feedstock flexibility and supply‑chain continuity. Pivoting to specialty chemicals, bioplastics and recycled plastics.
• 

  15 May 2026

  Ercros Q1 2026: €13.6m loss

  Q1: contribution €52m; adj. EBITDA −€1m; liquidity €45m. Weak demand, high energy costs, non‑EU competition. Bondalti bid 77.23% accepted. New board aims to delist, restore profitability, integrate
• 

  15 May 2026

  Iberdrola completes phase 1 of Noronha Verde, installs 4,800 solar panels

  Project pairs solar with battery storage on Fernando de Noronha to reach 22 MWp/49 MWh, replace biodiesel, supply ~9,000 homes; €50M (R$350M) investment, completion by end-2026.
• 

  15 May 2026

  Genentech’s Tecentriq approved by FDA as ctDNA‑guided adjuvant therapy for MIBC

  FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
• 

  15 May 2026

  Eni completes investment in Nouveau Monde Graphite

  US$70M subscription (of US$309.5M round) buys ~11.6% stake and board seat; secures graphite/anode material supply and supports Brindisi Gigafactory and supply-chain diversification.
• 

  15 May 2026

  Technip Energies awarded FNTP for Commonwealth LNG 9.5 Mtpa EPC

  FID enables full execution; scope: six identical modular SnapLNG trains to accelerate schedule, reduce costs and improve predictability, advancing modular LNG delivery models.
• 

  15 May 2026

  EnviTec Biogas: solid 2025; regulatory setbacks dent 2026, growth expected from 2027

  Total output +6.8% to €376.4M; revenues -7.4% to €312.6M; EBT €26.0M (prev €44.0M) after ~€8M provision; dividend suspended. 2026 guidance: revenues €330–370M, EBT €5–15M.
• 

  14 May 2026

  Repsol: Refining is strategic for Spain and Europe

  Chairman urged removing investment barriers and securing supply amid Iran crisis. CEO forecasts 6–9% DPS growth to 2028, 30–40% of CFO for returns; AGM ok'd dividends, €350m buyback
• 

  14 May 2026

  OrganOx appoints Naoya Iwata CEO & President

  Effective June 1, 2026, he brings 20+ years at Terumo in sales, strategy and business development, including Chief of Staff experience, to scale commercial growth and NMP adoption.
• 

  14 May 2026

  MOL adds biomethane unit to Szarvas biogas plant

  Szarvas plant will add a biomethane unit to clean biogas to grid quality, yielding over 7 million m3/yr (≈8,500 households), boosting local renewables and energy security; operational by year-end.
• 

  14 May 2026

  Petrobras restarts fertilizer production at Fafen-BA

  Plant resumed operations after R$100M investment, running at 90% capacity and meeting ~5% of national fertilizer demand. Plans include E&P, biodiesel, waste-oil programs and cultural funds.
• 

  14 May 2026

  PureCycle: NJDEP Qualifies PureFive® Resin as Recycled Content

  NJDEP grants one-year conditional PCR designation under NJ recycled-content law; firm will seek permanent approval. Resin cleared for food-contact rigid packaging; 10.5M lb NJ feedstock sourced 2025
• 

  14 May 2026

  LanzaTech Q1 2026 Results

  Q1: closed $30M equity raises (plus up to $20M option), going‑concern resolved; revenue $12M; net loss narrowed to $14.7M; Adj. EBITDA loss $7.9M; OpEx down 59%; India, UK, Japan milestones.
• 

  14 May 2026

  Iberdrola begins commissioning Tâmega wind‑hydro complex

  Tâmega Norte enters commissioning as the Iberian Peninsula's first grid-connected wind‑hydro hybrid: 195 MW (27×7.2 MW), ~414 GWh/yr; €346M for both farms; >230,000 t CO2/yr avoided.
• 

  14 May 2026

  Chugai, Nippon Shinyaku file Gazyva (obinutuzumab) for idiopathic nephrotic syndrome

  Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.
• 

  14 May 2026

  Johnson Matthey 2026 PGM Market Report

  PGM prices surged; platinum hit record. 2026: deficits likely for platinum, ruthenium, iridium; palladium and rhodium may have small surpluses. Strong prices boost recycling; industrial demand firm.
• 

  14 May 2026

  Sinopec confirms 2,356.87 bcm proven reserves at Ziyang Dongfeng ultra-deep shale gas field

  Cambrian Qiongzhusi shale at 4,500–5,200 m poses high-temp, high-pressure, hard-to-drill reservoir challenges. Team developed new geological model, AI imaging and ultra‑deep drilling/fracturing tech.
• 

  13 May 2026

  thyssenkrupp Polysius spins off sustainable process technologies into thyssenkrupp Calvion

  Effective 1 May 2026, a carve‑out bundles Oxyfuel and other CO₂‑reduction process technologies into a dedicated unit to speed development, industrialization and market deployment for heavy industries.
• 

  13 May 2026

  Worley wins engineering contract for Orbia's Louisiana LiPF6 plant

  Engineering, supply-chain, modularization, construction and automation support for a new large-scale battery electrolyte production facility in the US to bolster battery materials supply.
• 

  13 May 2026

  EnviTec Biogas opens Bio-LNG filling station in Holdorf

  New Bio-LNG station in Holdorf offers A1/B214 access, 30,000 kg storage and two pumps; supports LNG truck fleet, enabling ~200 t CO2 savings per truck/year (at 125,000 km).
• 

  13 May 2026

  Avantium sells Ray Technology IP to UPM

  Sale transfers Ray Technology patents for bio-based MEG/MPG (up to end‑2023). Seller refocuses on FDCA/PEF; €2.7M proceeds used to repay debt (€2.0M) and dismantle pilot (€0.7M).